BRIDGEWATER, NJ -- (MARKET WIRE) -- October 26, 2006 -- Sapphire Therapeutics, Inc., a private biopharmaceutical company that develops compounds acting within the ghrelin pathway for metabolic and oncologic diseases, has licensed to Ono Pharmaceutical Co., Ltd. (Osaka, Japan), a novel drug candidate for treating cancer anorexia/cachexia.
